Research progress on neoadjuvant immunotherapy for esophageal cancer
10.3760/cma.j.cn113030-20220411-00130
- VernacularTitle:食管癌新辅助免疫治疗研究进展
- Author:
Liang YI
1
;
Hui HUANG
;
Zhiyong YUAN
;
Wencheng ZHANG
Author Information
1. 天津医科大学肿瘤医院放疗科，国家恶性肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津市恶性肿瘤临床医学研究中心，天津 300060
- Keywords:
Esophageal neoplasms;
Neoadjuvant therapy;
Neoplasms / immunotherapy;
Research progress
- From:
Chinese Journal of Radiation Oncology
2023;32(7):638-643
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant therapy, especially neoadjuvant chemoradiotherapy, has become the standard preoperative treatment for locally advanced resectable esophageal cancer, whereas the recurrence and distant metastasis rates after surgery remain high. In recent years, programmed cell death protein 1 (PD-1) / programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors have been widely adopted in immunotherapy for cancer. Whether PD-1/PD-L1 immune checkpoint inhibitors combined with neoadjuvant chemotherapy / neoadjuvant chemoradiotherapy could further improve clinical efficacy, increase the complete surgical resection rate and safety are current research hotspots. In this article, neoadjuvant immunotherapy combined with chemotherapy / radiochemotherapy for esophageal cancer was reviewed.
